Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when WHWK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsWhitehawk raises $87.5M in PIPE financing with 45% insider participation at $3.92/share
Filed May 13, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
high
Company sold 4.3M shares and 18M pre-funded warrants at $3.92 per unit for $87.5M total proceeds, closing expected May 14, 2026. Pre-funded warrants are exercisable at $0.0001, functioning as common stock equivalents.
Item 1.01 verify on EDGAR → -
high
Insiders committed $39.75M (45% of total raise) including executives and directors, signaling management confidence. Independent directors approved the insider participation.
Item 1.01 verify on EDGAR → -
high
Approximately 22.3M new shares will be issued (combining direct shares and warrant equivalents), representing significant dilution to existing shareholders depending on current share count.
Item 1.01 verify on EDGAR → -
medium
Company must register shares for resale within 30 days of closing and obtain SEC effectiveness within 60-90 days, potentially creating selling pressure once registration is effective.
Item 1.01 verify on EDGAR → -
medium
Executives and directors agreed to 60-day lock-up preventing securities sales after closing, limiting immediate insider selling pressure.
Item 1.01 verify on EDGAR →
Summary
Whitehawk Therapeutics secured $87.5 million through a private placement, selling common shares and pre-funded warrants at $3.92 per unit to institutional and insider investors. The financing is notable for substantial insider participation—executives and directors are purchasing nearly half the offering at $39.75 million, a strong vote of confidence that independent directors approved.
The transaction will close May 14, 2026, subject to customary conditions. Retail investors should understand this represents meaningful dilution of approximately 22.3 million shares (or share equivalents). However, the insider commitment and 60-day lock-up period suggest management believes the capital will drive value creation that offsets dilution.
The company must register these shares for resale within 30-60 days, which could create selling pressure once investors can freely trade. Watch for the company's disclosure of how it plans to deploy the $87.5 million—whether for clinical trials, business development, or general operations—and monitor trading volume once the resale registration becomes effective to gauge investor appetite at current valuations.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Whitehawk raised $87.5M via PIPE financing selling 4.3M shares and 18M pre-funded warrants at $3.92/share, with insiders purchasing $39.75M.
Added in current filing · verify on EDGAR →
In addition, pursuant to the terms of the Purchase Agreement, the executive officers and directors of the Company have entered into “lock-up” arrangements, which generally prohibit the sale, transfer or other disposition of securities of the Company, subject to certain exceptions, for a period of 60 days following the closing of the PIPE Financing.
Company executives and directors agreed to a 60-day lock-up period preventing them from selling company securities after the financing closes. This restriction helps prevent immediate selling pressure from insiders following the capital raise.
Added in current filing · verify on EDGAR →
Pursuant to the Registration Rights Agreement, the Company will prepare and file a resale registration statement with the Securities and Exchange Commission (the “SEC”) on or prior to 30 days following the closing of the PIPE Financing, and the Company will use its commercially reasonable efforts to cause this registration statement to be declared effective by the SEC within 60 calendar days of the closing of the PIPE Financing (or within 90 calendar days if the SEC reviews the registration statement), subject to acceleration under certain circumstances.
The company committed to register the newly issued shares for resale within 30 days of closing and have the registration declared effective within 60-90 days. This allows PIPE investors to sell their shares publicly once registered, which could create selling pressure on the stock.
Added in current filing · verify on EDGAR →
4,330,866 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $3.92 per share, and (ii) 17,991,021 pre-funded warrants to acquire Common Stock
The financing will result in approximately 22.3 million new shares (combining direct shares and pre-funded warrants that are essentially equivalent to shares). This represents significant dilution to existing shareholders, though the magnitude depends on the company's pre-existing share count.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Whitehawk Therapeutics disclosed a private placement (PIPE) financing with unregistered equity issuance under Section 4(a)(2).
Added in current filing · verify on EDGAR →
The shares to be issued by the Company in the PIPE Financing will be issued in private placements exempt from registration under Section 4(a) (2) of the Securities Act promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a) (2) of the Securities Act, and other applicable requirements were met.
The company is conducting a private investment in public equity (PIPE) financing, issuing shares without SEC registration by relying on the private placement exemption. This means the shares are being sold to a limited group of investors rather than through a public offering. The 8-K references Item 1.01 for additional details about the PIPE transaction, but those details are not included in this excerpt.
Event · Item 7.01 — Regulation FD Disclosure
Whitehawk announced execution of a Purchase Agreement and PIPE Financing via press release; details furnished under Reg FD.
Added in current filing · verify on EDGAR →
On May 13, 2026, the Company issued a press release announcing the execution of the Purchase Agreement and the PIPE Financing.
Whitehawk disclosed it has executed a Purchase Agreement and arranged a PIPE (Private Investment in Public Equity) Financing.1) for details. PIPE financings typically provide capital to public companies through private placement of securities.
Added in current filing · verify on EDGAR →
Such forward-looking statements include, but are not limited to the expected closing date, gross proceeds of the PIPE Financing, the anticipated use of proceeds of the PIPE Financing, and the registration for resale of the securities being issued and sold in the PIPE Financing.
The company disclosed forward-looking statements regarding the PIPE Financing's expected closing date, gross proceeds, use of proceeds, and registration for resale of securities. These are subject to risks including the possibility that closing conditions are not satisfied. Investors should note that actual outcomes may differ from expectations.
Added in current filing · verify on EDGAR →
Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation, market, market risks and other market conditions; the risk that the conditions to the closing of the PIPE Financing are not satisfied
Whitehawk cautioned that the PIPE Financing may not close if conditions are not satisfied, and that market risks and other uncertainties could affect outcomes. This is standard disclosure language but highlights execution risk on the announced financing.
Event · Item 9.01 — Financial Statements and Exhibits
Whitehawk Therapeutics disclosed a securities purchase agreement dated May 12, 2026, involving pre-funded warrants and registration rights.
Added in current filing · verify on EDGAR →
Securities Purchase Agreement, dated May 12, 2026 and each purchaser identified on Exhibit A thereto.
The company entered into a securities purchase agreement on May 12, 2026, with purchasers listed in Exhibit A. This indicates a capital-raising transaction, though the 8-K does not disclose the amount raised, number of securities sold, or purchaser identities in the body text.
Added in current filing · verify on EDGAR →
Form of Pre-Funded Warrant to Purchase Common Stock.
The company issued pre-funded warrants to purchase common stock as part of the securities transaction. Pre-funded warrants are typically used in registered direct offerings and allow holders to purchase shares at a nominal exercise price, effectively functioning as common stock equivalents. This will result in dilution to existing shareholders when exercised.
Added in current filing · verify on EDGAR →
Form of Registration Rights Agreement, by and among Whitehawk Therapeutics, Inc. and the purchasers thereto.
The company granted registration rights to the purchasers, obligating Whitehawk to register the resale of the securities with the SEC. This is standard in private placements and allows purchasers to sell their shares publicly, potentially increasing selling pressure on the stock.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify